What stocks are in the AI Drug Discovery watchlist?

The AI Drug Discovery watchlist tracks 4 tickers on QuantAbundancia: ABCL, SDGR, GENB, RXRX.

Watchlist

AI Drug Discovery

Pure-play AI-driven drug-discovery platforms - generative biology, computational chemistry, antibody design, and protein-structure prediction applied to therapeutic pipelines. Companies where AI is the differentiator, not a buzzword bolted onto a traditional biotech. Seed members are 2026's 4 cleanest public listings on this thesis; the basket will grow as new IPOs land and Insitro-class private names go public.

source: editorial 2026-05-18

Hypothetical· equal-weight buy at inception, mark-to-market today

May 18 → Aug 18 · 4/4 picks · equal-weight

+58.6%

AI Drug Discovery

+3.9%

SPY

+54.7%

alpha

topABCL+163.5%·SDGR+46.6%·GENB+18.2%

dragRXRX+5.8%·GENB+18.2%·SDGR+46.6%

Antibody discovery

1 pick

#4
ABCLAbCellera Biologics Inc.
Antibody platform - single-cell microfluidics + ML - pivoting from pure platform-royalty model toward direct internal pipeline. Canadian-listed. Lead ABCL635 on track for Phase 2 top-line Q3 2026 with multiple follow-ons (ABCL575, 688, 386, 5th candidate this year). CAD 655M total liquidity including government funding.
$11.12last

Computational chemistry

1 pick

#3
SDGRSchrödinger, Inc.
Physics-based molecular-design platform with 30+ years of R&D. Pharma + biotech + academia license the software (ACV +12% Q1 2026, transitioning to hosted); internal pipeline rides co-discovery royalties. Smallest mcap of the cohort but the most mature platform. Bunsen agentic-AI co-scientist early-access summer 2026.
$17.67last

Generative biology

1 pick

#1
GENBGenerate Biomedicines, Inc.
AI-engineered protein therapeutics. Feb 2026 IPO at $16 ($400M raised); Phase 3 SOLAIRIA-1/2 testing GB-0895 anti-TSLP in severe asthma. Amgen ($1.9B potential) + Novartis (>$1B) collabs anchor validation. The category-defining IPO that re-opened the AI-bio public window after a 2-year drought.
$16.08last

Phenomics platform

1 pick

#2
RXRXRecursion Pharmaceuticals, Inc.
Phenomics imaging + foundation models trained on internal cellular data. NVIDIA $50M strategic investment + BioHive-2 supercomputer collaboration. Q1 2026 revenue miss highlighted the gap between AI-platform narrative and actual pharma-collab monetization, but cash position ($665.2M) supports ~2 years of runway.
$3.09last

Frequently asked questions

What stocks are in the AI Drug Discovery watchlist?: The AI Drug Discovery watchlist tracks 4 tickers on QuantAbundancia: ABCL, SDGR, GENB, RXRX.
What is the AI Drug Discovery watchlist?: Pure-play AI-driven drug-discovery platforms - generative biology, computational chemistry, antibody design, and protein-structure prediction applied to therapeutic pipelines. Companies where AI is the differentiator, not a buzzword bolted onto a traditional biotech. Seed members are 2026's 4 cleanest public listings on this thesis; the basket will grow as new IPOs land and Insitro-class private names go public.

Related research

May 30, 2026·7 min read

IBM - a aposta na foundry quântica, e o que uma incumbente de US$ 278 bi realmente faz